Concepedia

Hiroya Taniguchi

HT

Statistics

Publications

22

Citations

845

H-Index

16

Active since

1991

Affiliations

Aichi Cancer Center(Current)

Shizuoka Cancer Center

National Cancer Center Hospital East

Saitama Cancer Center

Kyushu University

Hiroya Taniguchi is an author at Aichi Cancer Center specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

1991–2020

22

Publications

22

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi et al. · The Oncologist · 2017 · 105 citations · Full text

, , +12

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer

Kazunori Honda, Bishal Gyawali, Masashi Ando et al. · Journal of Global Oncology · 2019 · 89 citations · Full text

, , +17

Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison

Toshiki Masuishi, Hiroya Taniguchi, Satoshi Hamauchi et al. · Clinical Colorectal Cancer · 2016 · 74 citations

, , +10

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

Eric Van Cutsem, Takayuki Yoshino, Heinz‐Josef Lenz et al. · Annals of Oncology · 2018 · 64 citations · Full text

, , +12

Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer

Keiji Sugiyama, Yukiya Narita, Seiichiro Mitani et al. · Anticancer Research · 2018 · 58 citations · Full text

, , +15

1–5 of 22